Hybrid Approaches to Clinical Trial Supply- Steven Jacobs Interviews Stuart Pullen

Posted: 10/29/2013
Ahead of the Clinical Trial Supply Europe event, Pharma IQ presents interviews filmed live at last year's CTS event. In this interview Steven Jacobs, President at Global Biopharmaceutical Resources Inc. interviews Stuart Pullen, Clinical Trial Supply Project Lead at Allergan about the difficulties in forecasting changing priorities and requirements in clinical trials. Stuart describes what are the characteristics of a good supply team and the two discuss the hybrid approach of in-house and outsourced capabilities at Allergan along with tips for dealing with vendors.
To continue viewing this content please fill out the form below and become an Pharma IQ member.
Or if you're already a Pharma IQ member, sign in below to download.
Join

By entering in your information and submitting the form, you give the sponsor permission to contact you regarding their product and you agree to our User Agreement, Privacy Policy, and Cookie Policy.

Ahead of the Clinical Trial Supply Europe event, Pharma IQ presents interviews filmed live at last year's CTS event. In this interview Steven Jacobs, President at Global Biopharmaceutical Resources Inc. interviews Stuart Pullen, Clinical Trial Supply Project Lead at Allergan about the difficulties in forecasting changing priorities and requirements in clinical trials. Stuart describes what are the characteristics of a good supply team and the two discuss the hybrid approach of in-house and outsourced capabilities at Allergan along with tips for dealing with vendors.

Contributor: